| 0.67 -0.038 (-5.41%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.29  |
1-year : | 1.63 |
| Resists | First : | 1.1 |
Second : | 1.39 |
| Pivot price | 0.86 |
|||
| Supports | First : | 0.63 |
Second : | 0.52 |
| MAs | MA(5) : | 0.72 |
MA(20) : | 0.93 |
| MA(100) : | 1.03 |
MA(250) : | 1.04 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 6.4  |
D(3) : | 5.4 |
| RSI | RSI(14): 20.4 |
|||
| 52-week | High : | 1.87 | Low : | 0.45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GOSS ] has closed above bottom band by 11.3%. Bollinger Bands are 34.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.71 |
| Low: | 0.62 - 0.63 | 0.63 - 0.63 |
| Close: | 0.66 - 0.67 | 0.67 - 0.68 |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Mon, 01 Apr 2024
Will Gossamer Bio Inc (GOSS) Stay at the Top of the Healthcare Sector? - InvestorsObserver
Thu, 28 Mar 2024
Gossamer Bio EVP sells over $7,000 in company stock By Investing.com - Investing.com
Tue, 19 Mar 2024
Gossamer Bio executive sells over $5,000 in company stock By Investing.com - Investing.com
Tue, 12 Mar 2024
Gossamer Bio Welcomes New Board Members, Enhances Leadership - TipRanks.com - TipRanks
Tue, 12 Mar 2024
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors - Business Wire
Thu, 07 Mar 2024
Should You Buy Gossamer Bio (GOSS) After Golden Cross? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 226 (M) |
| Shares Float | 191 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 93.1 (%) |
| Shares Short | 10,760 (K) |
| Shares Short P.Month | 14,300 (K) |
| EPS | -1.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.2 % |
| Return on Equity (ttm) | -480.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -159 (M) |
| Levered Free Cash Flow | -85 (M) |
| PE Ratio | -0.57 |
| PEG Ratio | -0.3 |
| Price to Book value | 2.39 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|